|
|
|
Volumn 19, Issue 13, 2005, Pages
|
|
First-line treatment for advanced non-small-cell lung cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CARBOPLATIN;
ENZYME INHIBITOR;
EPIDERMAL GROWTH FACTOR RECEPTOR;
MONOCLONAL ANTIBODY;
PACLITAXEL;
DRUG ANTAGONISM;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
MORTALITY;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL;
REVIEW;
SURVIVAL RATE;
TIME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE III;
ENZYME INHIBITORS;
HUMANS;
LUNG NEOPLASMS;
PACLITAXEL;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SURVIVAL RATE;
TIME FACTORS;
|
|
EID: 33644870156
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (41)
|
|
References (40)
|
